ew global tavr growth headlin anoth stellar out-performance despit
exceedingli high expect tavr strength flow bottom line
ew also deliv nice beat continu see upsid number throughout
remaind believ posit estim revis sustain
stock momentum reiter outperform/pt
ew look prime carri superb tavr momentum end
ew post stellar tavr growth amount well ahead
street estim manag note strength broad-bas
across geographi total market like grow rang tavr
perform particularli strong ew estim procedur volum growth
market match growth observ ew tavr unit clearli
benefit low risk segment unlock partner superior data
earli august fda approv look remaind year ew expect
tavr sale toward top end previou rang impli
underli growth nearli remain optimist ew experi robust
growth tavr franchis due strengthen util trend
deeper penetr intermediate-risk indic follow stellar low-risk data
bigger boost low risk util post approv era
ew confid top-end total revenu tavr guidanc rang
manag revis full-year revenu guidanc toward higher end
previou guidanc anticip ep
previous updat guidanc rang reflect strong ytd perform
tavr sale toward top end rang underli growth
slightli pressur guidanc manag expect tmtt revenu
vs previous compani continu pursu disciplin
introduct premium price strategi pascal transcathet mitral system
europ see next bullet critic still expect grow hemospher
import driver strong growth critic continu trend
posit ew integr new featur platform surgic heart revenu guidanc
remain underli growth addit anticip
stronger top-lin upwardli revis ep guidanc rang benefit tax rate
toward bottom end previou guidanc rang tavr
outlook manag acknowledg still earli offer revis guidanc rang
suggest model low-double-digit global procedur growth next year consist
manag estim opportun addit like
growth slower first half due challeng comp period believ
outlook like conserv skew see stronger tailwind post
pleas see page report import disclosur
base outperform rate belief sustain ew high-single-digit
double-digit top-lin growth along double-digit ep growth trajectori driver
compani includ tavr market leadership age global elderli popul shift
aortic stenosi risk curv tavr rais tavr awar among patient
expect last year fda ce mark approv sapien intermedi risk aid
upsid trial prove favor believ ew share continu valu
premium median forward price-to-earnings multipl compani large-cap peer churn
intermedi risk market develop
wake surtavi data readout
updat mitral program timelin
maintain market share
us tavr market
strong adopt sapien high-risk/
inoper patient us
continu success roll-out sapien
intermedi risk
top-lin growth acceler
ew mitral program develop faster
top-lin growth deceler
expect
ew lead medic devic compani manufactur heart valv repair
product replac repair diseas defect heart compani also provid
hemodynam monitor system cardiovascular function measur hospit
set headquart irvin california ew oper roughli countri
employe world-wide compani found edward
laboratori acquir baxter spun baxter earli
ew sale product world-wide posit
disciplin pascal launch limit tmtt pipelin updat keep us posit ew
sale transcathet mitral tricuspid therapi tmtt total result
reflect continu roll-out pascal receiv ce mark approv late februari
subsequ launch control basi europ control roll-out
ew remain focus physician train procedur success patient outcom
manag also indic physician feedback pascal remain strong
compani premium-pric strategi contribut slightli lower expect
revenu perform cardioband compani indic revenu contribut
product today rel small tmtt revenu guidanc revis
minor hole ew print mitral pipelin
ew progress patient enrol clasp iid pivot trial evalu pascal
primari degen mitral diseas enrol also begun clasp iif
studi determin pascal role secondari function mitral diseas edward
addit remain track initi pivot trial sapien transcathet
replac platform year end feasibl work evoqu reportedli
increas price target ew follow result post
low risk approv even convict upsid
forecast ew ou tavr unit along associ benefit
compani bottom line target partli base discount cash flow analysi
valu base savr critic tavr busi also remain optimist
ew one best posit capit burgeon multi-billion dollar tmvr
opportun new target impli price-to-earnings multipl appli adjust
ep estim repres signific premium median price-to-earnings multipl
ew large-cap medic devic peer group roughli exclud ew
anticip meaning out-performance ew outyear
result favor consensu estim revis could start post ew
posit bottom line revis midpoint therefor consid multipl
choic reason
compani report thomson eikon cowen compani
prior quarterprior year chg chg heart heart good gross gross margin oper net interest expens net expens pre-tax incom tax incom tax net incom dilut share estimatesour estimatesactu cowen
compani report thomson eikon cowen compani
good dilut share analysisgross analysistot forma cowen
compani report thomson eikon cowen compani
heart valv heart mitral critic analysissurg heart valv cowen
compani report thomson eikon cowen compani
usecent tavr enu cardioband pascal enu total enu growth tavr enu growth cardioband growth pascal growth trial/hd usequarterli clinic trial usecent commerci total commerci growth total enu growth usecent commerci total worldcommerci usecent world ww enu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market setback develop tmvr
product prevent commerci fluctuat foreign exchang rate
